Laminar Drainage Implant: Safety of a Novel Surgical Treatment for Refractory Glaucoma.

May 23, 2017 updated by: SÉRGIO JACOBOVITZ, Federal University of Minas Gerais

Purpose: To assess the feasibility of a surgical technique and present the preliminary safety results of a new glaucoma device devoid of a tube in painful blind eyes.

Methods: Fifteen end-stage glaucomatous eyes without light perception vision were treated with a novel laminar drainage implant. Intraocular pressure was measured preoperatively and up to 24 months after surgery using a Goldmann applanation tonometer. A scale ranging from 0 to 10 was used to evaluate ocular pain. Conjunctival hyperemia, discharge, erosion or retraction, aqueous humor leakage, corneal edema, hyphema, anterior chamber cells and depth, dislocation of the implant, and filtering bleb height were assessed by slit-lamp biomicroscopy. Anterior segment optical coherence tomography was also assessed.

Study Overview

Detailed Description

Methods: Light perception was tested in the preoperative assessment. The following parameters were evaluated at the pre- and postoperative visits: morning Goldmann applanation tonometry; anterior segment biomicroscopy, gonioscopy, and eye pain intensity. Postoperative visits occurred on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years. The criteria for IOP reduction success were 15 mmHg and a 20% reduction compared to the baseline preoperative IOP. Biomicroscopy variables included the presence or absence of hyperemia, discharge, conjunctival erosion and retraction, aqueous humor leakage (Seidel test), corneal edema, hyphema, AC reaction and depth, and device dislocation. A shallow AC was considered a Spaeth classification grade of I or II and a flat AC was considered grade III. A filtering bleb height above the LDI profile was considered elevated; otherwise, it was classified as flat. Gonioscopy was performed preoperatively and postoperatively. Ocular pain intensity was assessed before and after surgery using a verbal Numerical Rating Scale ranging from zero to 10, with zero representing the absence of pain and 10 representing the worst eye pain ever felt before surgery.

Anterior segment optical coherence tomography (AS-OCT) (Visante®, Carl Zeiss Meditec®, Inc., Dublin, CA, USA) was performed postoperatively at the highest resolution (enhanced high-resolution corneal mode).

Reoperations to unblock the internal ostium were not considered failures; thereafter, the day of the second surgery was considered postoperative day 0.

LDI A human LDI was designed by one of the authors (S.J.) after a preclinical trial in rabbits with a similar device. It is a 150-µm-thick foil made of polymethylmethacrylate (PMMA), composed of three functional areas (Fig. 1): 1) the tip, which has a triangular shape and is inserted into the AC angle; 2) the intermediate portion, which has a rectangular shape (4.5 mm long × 4.0 mm wide) and is positioned inside a scleral tunnel; and 3) the posterior plate, which has a round shape (diameter = 12.5 mm) and is positioned between the sclera and conjunctiva. The LDI plate is positioned only 4.5 mm from the corneoscleral limbus and no allograft coverage is necessary. Its hypothetical mechanism of action is similar to those of popular GDIs and shunts the aqueous humor from the AC to the subconjunctival plate. The difference between their designs is the absence of a tube in the LDI. Thus, aqueous humor drainage is supposed to occur in the space between the inner walls of the scleral tunnel and LDI and/or thought is cleft.

LDI Surgery All surgeries were performed under local peribulbar anesthesia by the same surgeon (S.J.).

Statistical Analysis The sample size was calculated based on IOP standard deviation values from the first seven patients who were operated on (an internal pilot study) while considering 15 mmHg as the minimal clinically relevant difference to be detected.

Histogram inspection and Shapiro-Wilk tests were used to assess the assumption of the normality of variables. Wilcoxon's rank-sum test was used to compare the median pain intensity at each postoperative visit to that at the preoperative visit. Conjunctival hyperemia, AC cells, corneal edema, and hyphema variables were analyzed using McNemar's test. The comparison between the pre- and postoperative mean IOP was performed using Student's two-tailed paired t-test. Results were analyzed using SPSS® (Statistical Package for the Social Sciences) for Windows version 18.0 (IBM, Chicago, IL, USA) and the alpha level (type I error) was set at 0.05.

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • patients aged 18 years or older with a painful blind eye refractory to clinical treatment and an intraocular pressure (IOP) ≥ 30 mmHg.

Exclusion Criteria:

  • eyes with extensive conjunctival scarring, a disorganized anterior segment, or retinal detachment identified by ophthalmoscopy or B-scan ultrasonography.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Device Feasibility
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: laminar drainage implant surgery
patients included and operated
A clear corneal traction suture was placed to achieve superior-temporal quadrant exposure, where a 90° conjunctival fornix-based flap was made, associated with two radial relaxing incisions. A half-thickness scleral tunnel (4.5 mm from the limbus and 4.0 mm wide) was made using a crescent blade and a superior-temporal iridectomy was performed through . Then, the tunnel end was shunted to the AC using a 1.5-mm-wide blade with a sharp tip. The LDI was inserted into the scleral tunnel so that its tip was positioned in the AC periphery and the implant was anchored to the sclera using 7-0 polypropylene thread with two separate sutures. Next, fistula function was assessed by the aqueous humor leakage test at the scleral tunnel entry site. Then, the conjunctiva was repositioned and running sutures were performed with 7-0 polyglactin for the relaxing incisions and mattress sutures were performed in the limbus using 10-0 nylon.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change for baseline of intra-ocular pressure (Goldmann applanation tonometry)
Time Frame: on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.
The criteria for IOP reduction success were 15 mmHg and a 20% reduction compared to the baseline preoperative IOP.
on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ocular pain intensity ratting change from baseline
Time Frame: on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.
Ocular pain intensity was assessed before and after surgery using a verbal Numerical scale.
on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.
Conjunctival discharge presence/absence change from baseline
Time Frame: on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.
conjunctival discharge was assessed by slit-lamp examination
on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.
Conjunctival erosion or retraction appearence after surgery
Time Frame: on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.
Presence or abscence of conjunctival tissue erosion or retraction, caused by the tested
on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.
Corneal edema presence change from baseline
Time Frame: on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.
assessed by slit-lamp biomicroscopy was classified as "present" or "abscent"
on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.
Anterior chamber depth (gonioscopy) change from baseline
Time Frame: on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.
A shallow AC was considered a Spaeth classification grade of I or II and a flat AC was considered grade III. A filtering bleb height above the LDI profile was considered elevated; otherwise, it was classified as flat
on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.
Optic coherence tomography (OCT) assessment qualitative study after surgery
Time Frame: from 6 months to two years after surgery.
OCT image were obtained in 8 patients after surgery in order to imaging study the implant and its relation with the eye structures.
from 6 months to two years after surgery.
Filtering bleg height variation from baseline
Time Frame: on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.
bleb heigh(if not above implant profile)t was slit-lamp assessed. classified as "elevated" (above implant profile) or "flat"
on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.
Conjunctival hyperemia change comparing to baseline
Time Frame: on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.
conjunctival inflamation graduation assessed by slit-lamp examination ("present or abscent")
on days 1, 3, 7, 14, and 30, once a month up to 6 months, and every 6 months from 6 months to 2 years.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sebastião C. Sobrinho, Md, Ph.D, Hospital São Geraldo-Universidade Federal de Minas Gerais

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2011

Primary Completion (Actual)

December 2, 2015

Study Completion (Actual)

September 2, 2016

Study Registration Dates

First Submitted

May 22, 2017

First Submitted That Met QC Criteria

May 23, 2017

First Posted (Actual)

May 25, 2017

Study Record Updates

Last Update Posted (Actual)

May 25, 2017

Last Update Submitted That Met QC Criteria

May 23, 2017

Last Verified

May 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glaucoma

Clinical Trials on Laminar drainage implant surgery.

3
Subscribe